We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+6.14%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.52B
AUM Growth
+$385M
Cap. Flow
+$3.2M
Cap. Flow %
0.04%
Top 10 Hldgs %
34.42%
Holding
155
New
17
Increased
44
Reduced
30
Closed
23

Top Buys

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$102M
2
CFN
CAREFUSION CORPORATION
CFN
+$68.7M
3
BMY icon
Bristol-Myers Squibb
BMY
+$60.2M
4
SHPG
Shire pic
SHPG
+$55.3M
5
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$54M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$146M
2
AGN
Allergan Inc
AGN
+$113M
3
PRTA icon
Prothena Corp
PRTA
+$72.4M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$63M
5
XLRN
Acceleron Pharma
XLRN
+$56.7M

Sector Composition

Rank Sector Weight
1 Healthcare 82.59%
2 Financials 0.08%
3 Technology 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SUPN icon
101
Supernus Pharmaceuticals
SUPN
$2.75B
$6.35M 0.07%
580,000
– –
CBST
102
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$6.28M 0.07%
90,000
– –
VCRA
103
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$5.91M 0.07%
447,500
– –
XLRN
104
DELISTED
Acceleron Pharma
XLRN
$5.84M 0.07%
171,800
-1,696,000
-91% -$56.7M
MDXG icon
105
MiMedx Group
MDXG
$645M
$5.64M 0.07%
795,400
– –
PBYI icon
106
CALL
Puma Biotechnology
PBYI
$398M
$5.61M 0.07%
+85,000
New +$6.04M
TEVA icon
107
CALL
Teva Pharmaceuticals
TEVA
$39.8B
$5.24M 0.06%
+100,000
New +$5.11M
VTRS icon
108
CALL
Viatris
VTRS
$20.8B
$5.16M 0.06%
100,000
-100,000
-50% -$4.91M
CPRX
109
DELISTED
Catalyst Pharmaceutical
CPRX
$4.79M 0.06%
1,895,000
– –
DVA icon
110
DaVita
DVA
$15.5B
$4.7M 0.06%
65,000
-78,000
-55% -$5.42M
PTCT icon
111
PTC Therapeutics
PTCT
$6.15B
$4.66M 0.05%
178,100
-652,000
-79% -$14M
IRWD icon
112
CALL
Ironwood Pharmaceuticals
IRWD
$596M
$4.6M 0.05%
358,200
– –
FATE icon
113
Fate Therapeutics
FATE
$267M
$4.37M 0.05%
692,900
– –
UPI
114
DELISTED
UROPLASTY INC-NEW
UPI
$3.65M 0.04%
1,363,500
– –
CRIS icon
115
Curis
CRIS
$9.82M
$3.63M 0.04%
975
– –
BSX icon
116
Boston Scientific
BSX
$69.4B
$3.47M 0.04%
271,700
– –
DSCI
117
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$3.47M 0.04%
300,000
– –
RNA
118
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
$3.33M 0.04%
+264,000
New +$2.14M
ANGO icon
119
CALL
AngioDynamics
ANGO
$596M
$3.27M 0.04%
200,000
– –
ANTH
120
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$3.16M 0.04%
116,594
– –
LUMO
121
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$2.65M 0.03%
+11,111
New +$2.26M
BLRX
122
BioLineRX
BLRX
$12.3M
$2.36M 0.03%
1,892
– –
CERS icon
123
CALL
Cerus
CERS
$577M
$2.08M 0.02%
500,000
– –
AMRN
124
Amarin Corp
AMRN
$300M
$704K 0.01%
20,000
– –
ALBO
125
DELISTED
Albireo Pharma Inc
ALBO
$453K 0.01%
6,990
-6,343
-48% -$441K
2 3 4
5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2014 Portfolio in Review

As of Q2 2014, OrbiMed held 155 positions worth $8.52B, up 4.7% from $8.13B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q2 2014 filing shows 17 new, 44 increased, 30 reduced and 23 closed positions. Its largest new stake was Alkermes: 433,300 shares worth $21.8M. The largest sale was Gilead Sciences, an estimated $146M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 83% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q2 2014 buy was Alkermes: 433,300 shares worth $21.8M.
  • OrbiMed added most to Ironwood Pharmaceuticals in Q2 2014, an estimated $102M increase.
  • OrbiMed's biggest Q2 2014 reduction was Gilead Sciences, cutting an estimated $146M.
  • OrbiMed fully exited Prothena Corp in Q2 2014, selling an estimated $72.4M.
  • OrbiMed's ten largest holdings make up 34% of its $8.52B portfolio in Q2 2014.
  • OrbiMed opened 17 new positions and closed 23 in Q2 2014.
  • OrbiMed's portfolio value rose 4.7% quarter-over-quarter to $8.52B.

Based on OrbiMed's 13F filing for Q2 2014, filed 14 Aug 2014.